MX2018009189A - Compuestos de anillo de siete miembros de pirimidina. - Google Patents

Compuestos de anillo de siete miembros de pirimidina.

Info

Publication number
MX2018009189A
MX2018009189A MX2018009189A MX2018009189A MX2018009189A MX 2018009189 A MX2018009189 A MX 2018009189A MX 2018009189 A MX2018009189 A MX 2018009189A MX 2018009189 A MX2018009189 A MX 2018009189A MX 2018009189 A MX2018009189 A MX 2018009189A
Authority
MX
Mexico
Prior art keywords
preparation
pharmaceutical composition
compounds
method therefor
pyrimidine
Prior art date
Application number
MX2018009189A
Other languages
English (en)
Inventor
Deng Xianming
Zhou Dawang
Chen Lanfen
He Zhixiang
FAN Fuqin
Original Assignee
Ani New Star Pharmaceutical Dev Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ani New Star Pharmaceutical Dev Co Ltd filed Critical Ani New Star Pharmaceutical Dev Co Ltd
Publication of MX2018009189A publication Critical patent/MX2018009189A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Abstract

La presente invención se relaciona a compuestos (I) capaces de inhibir la actividad de la proteína cinasa Mst1/2, un método de preparación de los mismos, una composición farmacéutica que comprende los compuestos, y usos de los compuestos y la composición farmacéutica que comprende los compuestos en la preparación de fármacos para promover la reparación y regeneración de tejidos y órganos, promoviendo la proliferación de células madre y diferenciación de células somáticas, inmunosupresión, y prevenir o tratar enfermedades relacionadas con trastornos nerviosos e isquemia local.
MX2018009189A 2016-03-04 2017-03-02 Compuestos de anillo de siete miembros de pirimidina. MX2018009189A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610121108 2016-03-04
PCT/CN2017/075416 WO2017148406A1 (zh) 2016-03-04 2017-03-02 嘧啶类七元环化合物、其制备方法、药用组合物及其应用

Publications (1)

Publication Number Publication Date
MX2018009189A true MX2018009189A (es) 2018-11-09

Family

ID=59743511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009189A MX2018009189A (es) 2016-03-04 2017-03-02 Compuestos de anillo de siete miembros de pirimidina.

Country Status (13)

Country Link
US (1) US10975092B2 (es)
EP (1) EP3424929A4 (es)
JP (1) JP2019512459A (es)
KR (1) KR20180114057A (es)
CN (1) CN107151250B (es)
AU (1) AU2017226499B2 (es)
CA (1) CA3012516A1 (es)
HK (1) HK1249499A1 (es)
MX (1) MX2018009189A (es)
RU (1) RU2748696C2 (es)
TW (1) TWI748996B (es)
WO (1) WO2017148406A1 (es)
ZA (1) ZA201805600B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311901A (zh) * 2016-04-07 2019-02-05 达纳-法伯癌症研究所有限公司 嘧啶并-二氮杂卓酮激酶骨架化合物及治疗pi3k介导的病变的方法
WO2018075608A1 (en) * 2016-10-18 2018-04-26 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders
CN111039944B (zh) * 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
CA3134221A1 (en) * 2019-05-10 2020-11-19 Dana-Farber Cancer Institute, Inc. Small-molecule focal adhesion kinase (fak) inhibitors
CN114728009A (zh) * 2019-08-08 2022-07-08 李晓祥 预防或治疗与组织损伤相关的疾病和紊乱
CN113717941B (zh) * 2020-05-26 2023-11-14 中科院合肥技术创新工程院 一种用于喉癌上皮细胞的培养基、培养方法及其应用
KR102498531B1 (ko) * 2020-06-29 2023-02-13 한국과학기술연구원 단백질 카이네이즈 trkc에 선택적인 억제제로서의 신규 피리미도디아제핀 유도체

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101257948A (zh) * 2005-02-18 2008-09-03 阿特努奥恩公司 嘧啶并二氮䓬衍生物及吲哚并蝶啶化合物
US20080242608A1 (en) 2006-06-02 2008-10-02 Azad Bonni Methods and compositions for treating and preventing neurologic disorders
US8563542B2 (en) * 2007-09-28 2013-10-22 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
WO2010080712A2 (en) 2009-01-06 2010-07-15 Dana Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
CA2902599C (en) * 2013-03-15 2023-03-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2015117087A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives

Also Published As

Publication number Publication date
RU2018124591A3 (es) 2020-07-24
RU2018124591A (ru) 2020-04-06
EP3424929A1 (en) 2019-01-09
RU2748696C2 (ru) 2021-05-28
TWI748996B (zh) 2021-12-11
CA3012516A1 (en) 2017-09-08
JP2019512459A (ja) 2019-05-16
US10975092B2 (en) 2021-04-13
HK1249499A1 (zh) 2018-11-02
NZ744393A (en) 2021-09-24
ZA201805600B (en) 2023-02-22
US20200115386A1 (en) 2020-04-16
TW201731850A (zh) 2017-09-16
CN107151250A (zh) 2017-09-12
EP3424929A4 (en) 2019-08-07
AU2017226499B2 (en) 2020-10-22
AU2017226499A1 (en) 2018-09-20
KR20180114057A (ko) 2018-10-17
WO2017148406A1 (zh) 2017-09-08
CN107151250B (zh) 2020-03-27

Similar Documents

Publication Publication Date Title
MX2018009189A (es) Compuestos de anillo de siete miembros de pirimidina.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
PH12014501355B1 (en) Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors
MX2008012422A (es) Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa.
MX347708B (es) Proceso para preparar isoquinolinonas y formas solidas de isoquinolinonas.
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2018003186A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[ 4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer.
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2010068483A3 (en) Mlk inhibitors and methods of use
EA201790267A1 (ru) Новые модуляторы киназ
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
GEP20115283B (en) Pyrrolopyrimidine compounds and their uses
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
MX2018016419A (es) Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
CL2015000096A1 (es) Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
EP2563794A4 (en) INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS